PA21 Safety and Efficacy in Adult Chinese Subjects

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 286 participants.

Also called NCT03644264

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 286 participants (enrolled count) (from the registry)
Sponsor
Vifor Fresenius Medical Care Renal Pharma (from the registry)
Registry
  • NCT NCT03644264
Other papers using this trial's data
  • Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study Nephron, 2024 DOI, PubMed 37473746, PMC10794965 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03644264. Randomized; no masking; primary purpose treatment. Start 2018-08-31 (actual); primary completion 2020-08-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PA21 Safety and Efficacy in Adult Chinese Subjects
Condition
Chronic Kidney Disease Requiring Chronic Dialysis
Condition
Hyperphosphatemia
Intervention (Drug)
PA21
Intervention (Drug)
sevelamer carbonate
Lead sponsor
Vifor Fresenius Medical Care Renal Pharma (class: industry)

Record details

Record id
cardio:ct-nct03644264
Content hash
b4da559590ae970f5999828a34176d2968b705d467b542d4b742d6584875f036